Brian C Callaghan1, Rong Xia2, Mousumi Banerjee2, Nathalie de Rekeneire3, Tamara B Harris4, Anne B Newman5, Suzanne Satterfield5, Ann V Schwartz6, Aaron I Vinik7, Eva L Feldman8, Elsa S Strotmeyer5. 1. Department of Neurology, University of Michigan, Ann Arbor, MI bcallagh@med.umich.edu. 2. School of Public Health, University of Michigan, Ann Arbor, MI. 3. University Bordeaux, ISPED, Centre INSERM U1219-Epidemiologie-Biostatistique, Bordeaux, France. 4. National Institute on Aging, Bethesda, MD. 5. School of Public Health, University of Pittsburgh, Pittsburgh, PA. 6. Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, CA. 7. Strelitz Diabetes Research Institute, Norfolk, VA. 8. Department of Neurology, University of Michigan, Ann Arbor, MI.
Abstract
OBJECTIVE: Previous studies demonstrate that the metabolic syndrome is associated with distal symmetric polyneuropathy (DSP). We aimed to determine the magnitude of this effect and the precise components involved. RESEARCH DESIGN AND METHODS: We determined the symptomatic DSP prevalence in the Health, Aging, and Body Composition (Health ABC) study (prospective cohort study, with subjects aged 70-79 years at baseline), stratified by glycemic status (glucose tolerance test) and the number of additional metabolic syndrome components (updated National Cholesterol Education Program/Adult Treatment Panel III definition). DSP was defined as neuropathic symptoms (questionnaire) plus at least one of three confirmatory tests (heavy monofilament, peroneal conduction velocity, and vibration threshold). Multivariable logistic and linear regression evaluated the association of metabolic syndrome components with DSP in cross-sectional and longitudinal analyses. RESULTS: Of 2,382 participants with neuropathy measures (mean age 73.5 ± 2.9 years, 38.2% black, 51.7% women), 21.0% had diabetes, 29.9% prediabetes, 52.8% metabolic syndrome, and 11.1% DSP. Stratified by glycemic status, DSP prevalence increased as the number of metabolic syndrome components increased (P = 0.03). Diabetes (cross-sectional model, odds ratio [OR] 1.65 [95% CI 1.18-2.31]) and baseline hemoglobin A1C (longitudinal model, OR 1.42 [95% CI 1.15-1.75]) were the only metabolic syndrome measures significantly associated with DSP. Waist circumference and HDL were significantly associated with multiple secondary neuropathy outcomes. CONCLUSIONS: Independent of glycemic status, symptomatic DSP is more common in those with additional metabolic syndrome components. However, the issue of which metabolic syndrome components drive this association, in addition to hyperglycemia, remains unclear. Larger waist circumference and low HDL may be associated with DSP, but larger studies with more precise metabolic measures are needed.
OBJECTIVE: Previous studies demonstrate that the metabolic syndrome is associated with distal symmetric polyneuropathy (DSP). We aimed to determine the magnitude of this effect and the precise components involved. RESEARCH DESIGN AND METHODS: We determined the symptomatic DSP prevalence in the Health, Aging, and Body Composition (Health ABC) study (prospective cohort study, with subjects aged 70-79 years at baseline), stratified by glycemic status (glucose tolerance test) and the number of additional metabolic syndrome components (updated National Cholesterol Education Program/Adult Treatment Panel III definition). DSP was defined as neuropathic symptoms (questionnaire) plus at least one of three confirmatory tests (heavy monofilament, peroneal conduction velocity, and vibration threshold). Multivariable logistic and linear regression evaluated the association of metabolic syndrome components with DSP in cross-sectional and longitudinal analyses. RESULTS: Of 2,382 participants with neuropathy measures (mean age 73.5 ± 2.9 years, 38.2% black, 51.7% women), 21.0% had diabetes, 29.9% prediabetes, 52.8% metabolic syndrome, and 11.1% DSP. Stratified by glycemic status, DSP prevalence increased as the number of metabolic syndrome components increased (P = 0.03). Diabetes (cross-sectional model, odds ratio [OR] 1.65 [95% CI 1.18-2.31]) and baseline hemoglobin A1C (longitudinal model, OR 1.42 [95% CI 1.15-1.75]) were the only metabolic syndrome measures significantly associated with DSP. Waist circumference and HDL were significantly associated with multiple secondary neuropathy outcomes. CONCLUSIONS: Independent of glycemic status, symptomatic DSP is more common in those with additional metabolic syndrome components. However, the issue of which metabolic syndrome components drive this association, in addition to hyperglycemia, remains unclear. Larger waist circumference and low HDL may be associated with DSP, but larger studies with more precise metabolic measures are needed.
Authors: Brian C Callaghan; Kevin A Kerber; Lynda L Lisabeth; Lewis B Morgenstern; Ruth Longoria; Ann Rodgers; Paxton Longwell; Eva L Feldman Journal: JAMA Neurol Date: 2014-09 Impact factor: 18.302
Authors: Solomon Tesfaye; Nish Chaturvedi; Simon E M Eaton; John D Ward; Christos Manes; Constantin Ionescu-Tirgoviste; Daniel R Witte; John H Fuller Journal: N Engl J Med Date: 2005-01-27 Impact factor: 91.245
Authors: K Van Acker; D Bouhassira; D De Bacquer; S Weiss; K Matthys; H Raemen; C Mathieu; I M Colin Journal: Diabetes Metab Date: 2009-03-17 Impact factor: 6.041
Authors: Edward W Gregg; Paul Sorlie; Ryne Paulose-Ram; Qiuping Gu; Mark S Eberhardt; Michael Wolz; Vicki Burt; Lester Curtin; Michael Engelgau; Linda Geiss Journal: Diabetes Care Date: 2004-07 Impact factor: 19.112
Authors: Marija Sajic; Amy E Rumora; Anish A Kanhai; Giacomo Dentoni; Sharlini Varatharajah; Caroline Casey; Ryan D R Brown; Fabian Peters; Lucy M Hinder; Masha G Savelieff; Eva L Feldman; Kenneth J Smith Journal: J Neurosci Date: 2021-03-30 Impact factor: 6.167
Authors: Stephanie Eid; Kelli M Sas; Steven F Abcouwer; Eva L Feldman; Thomas W Gardner; Subramaniam Pennathur; Patrice E Fort Journal: Diabetologia Date: 2019-07-25 Impact factor: 10.122
Authors: Brittney S Lange-Maia; Anne B Newman; John M Jakicic; Jane A Cauley; Robert M Boudreau; Ann V Schwartz; Eleanor M Simonsick; Suzanne Satterfield; Aaron I Vinik; Sasa Zivkovic; Tamara B Harris; Elsa S Strotmeyer Journal: Exp Gerontol Date: 2017-04-22 Impact factor: 4.032
Authors: Amy E Rumora; Giovanni LoGrasso; John M Hayes; Faye E Mendelson; Maegan A Tabbey; Julia A Haidar; Stephen I Lentz; Eva L Feldman Journal: J Neurosci Date: 2019-03-18 Impact factor: 6.167
Authors: Brian C Callaghan; Evan L Reynolds; Mousumi Banerjee; Ericka Chant; Emily Villegas-Umana; Thomas W Gardner; Kristen Votruba; Bruno Giordani; Rodica Pop-Busui; Subramaniam Pennathur; Eva L Feldman Journal: Diabetes Care Date: 2020-01-13 Impact factor: 19.112
Authors: Hannah C Timmins; David Mizrahi; Tiffany Li; Matthew C Kiernan; David Goldstein; Susanna B Park Journal: J Cancer Surviv Date: 2021-01-12 Impact factor: 4.442